
ORASURE TECHNOLOGIES INC
93
Recent developments include the reporting of third quarter 2026 net revenues, regulatory authorizations, and ongoing earnings call disclosures providing operational insights.
- OraSure Technologies reported third quarter 2026 net revenues of $30.9 million [N1].
- The company received FDA Emergency Use Authorization for its OraQuick Ebola 2.0 Antigen Test amid a Central Africa outbreak [N6].
- OraSure held $148.2 million in cash and equivalents as of September 30, 2026, with a current ratio of 8.58, indicating strong liquidity [S2].
- Recent earnings call transcripts and highlights provide detailed operational and strategic information for Q2 and Q1 2026 [N4][N5][N8].
- The company filed for FDA review of a molecular self-test and Colli-Pee device, signaling ongoing product development [N7].
OraSure Technologies Inc. is a developer and marketer of diagnostic products, including molecular and antigen tests. The company operates under stringent regulatory oversight primarily by the FDA and other global health authorities. Its product portfolio includes tests for infectious diseases, with recent regulatory milestones such as FDA Emergency Use Authorization for the OraQuick Ebola 2.0 Antigen Test. The company reports quarterly revenues and losses, reflecting ongoing investment in product development and commercialization. OraSure maintains strong liquidity and a robust cybersecurity governance framework. Regulatory compliance, product approvals, and market expansion are key operational focuses.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. OraSure Technologies Inc. reported third quarter 2026 net revenues of $30.9 million and a net loss of $13.1 million for the quarter ended September 30, 2026. The company holds substantial liquidity with $148.2 million in cash and equivalents and a current ratio of 8.58 as of September 30, 2026. Regulatory compliance and approvals remain critical to its operations, with recent FDA Emergency Use Authorization granted for its Ebola antigen test amid an outbreak. The company continues product development and regulatory submissions while managing cybersecurity and compliance risks [N1][S2][S1][N6].
The company demonstrates operational progress through recent revenue generation and regulatory authorizations, including FDA Emergency Use Authorization for its Ebola antigen test. Strong liquidity positions OraSure to support ongoing product development and commercialization efforts. Continued regulatory approvals and successful market adoption of new diagnostic products could enhance its competitive positioning and revenue streams. The company's governance and cybersecurity frameworks support risk management and operational resilience.
OraSure faces significant regulatory risks including potential delays or denials of product approvals, evolving regulatory requirements, and compliance challenges that could impact product commercialization. The company reported a net loss in the latest quarter, indicating ongoing profitability challenges. Market competition in diagnostics is intense, and failure to achieve broad market acceptance or regulatory clearance for new products could constrain growth. Additionally, regulatory disruptions or cybersecurity incidents could adversely affect operations and reputation.
OraSure's moat is anchored in its regulatory approvals and clearances, which create barriers to entry in the diagnostic testing market. Its portfolio of FDA-authorized and CE-marked diagnostic products, including rapid antigen and molecular tests, provides competitive differentiation. The company's established relationships with regulatory bodies and experience navigating complex approval processes support its market position. Additionally, its investments in cybersecurity and quality management systems help maintain operational integrity and trust with customers and regulators.
• Regulatory Approval Risks: The company depends on FDA and other regulatory approvals for its products. Delays, denials, or additional requirements could increase costs and limit market access [S1].
• Compliance and Operational Risks: Failure to comply with FDA regulations, quality standards, or cybersecurity requirements could result in sanctions, recalls, or operational disruptions [S1].
• Financial Performance Risks: The company reported net losses and faces challenges in achieving sustained profitability, which could impact its financial stability [S2].
• Market and Competitive Risks: Competition in the diagnostic testing market is intense, and failure to innovate or gain market acceptance could limit revenue growth.
Business trends: Continued regulatory approvals and product development in diagnostic testing, with recent revenue generation and FDA authorizations.
Execution milestones: Ongoing quarterly earnings disclosures, FDA submissions for new products, and maintenance of strong liquidity.
Key risks: Regulatory approval delays or denials, compliance challenges, profitability pressures, and competitive market dynamics.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- OraSure Technologies Inc. operates in the medical diagnostics sector, developing and commercializing diagnostic products including molecular and antigen tests.
- The company reported third quarter 2026 net revenues of $30.9 million as per recent news coverage [N1].
- OraSure reported a net loss of $13.1 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.19, according to its 10-Q filed on November 9, 2026 [S2].
- As of September 30, 2026, OraSure held $148.2 million in cash and equivalents and $215.3 million in current assets, with current liabilities of $25.1 million, resulting in a strong current ratio of 8.58 and a cash ratio of 6.27 [S2].
- The company has received FDA Emergency Use Authorization for its OraQuick Ebola 2.0 Antigen Test amid a Central Africa outbreak [N6].
- OraSure is subject to extensive FDA and other regulatory oversight, including requirements for product approvals, manufacturing compliance, labeling, and post-market surveillance [S1].
- The company faces regulatory risks including potential delays or denials of FDA approvals, changes in regulatory requirements, and compliance with international regulations such as the EU IVDR [S1].
- OraSure maintains a cybersecurity management program overseen by senior management and the Audit Committee, with regular reviews and updates to address information security risks [S1].
- Recent earnings call transcripts and highlights provide insights into operational performance and strategic focus areas [N4, N5, N8].
- The company filed for FDA review of a molecular self-test and Colli-Pee device, indicating ongoing product development efforts [N7].
Generated 2026-11-10
- N4
- N5
- N8
- S1 | 2026-03-09 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-10 | www.nasdaq.com | OraSure Technologies, Inc. Reports Third Quarter 2026 Net Revenues of $30.9 million | https://www.nasdaq.com/articles/orasure-technologies-inc-reports-third-quarter-2026-net-revenues-309-million
- N2 | 2026-11-05 | www.nasdaq.com | Prestige Consumer Healthcare (PBH) Beats Q2 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/prestige-consumer-healthcare-pbh-beats-q2-earnings-and-revenue-estimates
- N3 | 2026-08-20 | www.nasdaq.com | Sera Appoints Scott Gleason As CFO, Focuses On PreTRM Test Expansion | https://www.nasdaq.com/articles/sera-appoints-scott-gleason-cfo-focuses-pretrm-test-expansion
- N4 | 2026-08-13 | www.nasdaq.com | OraSure (OSUR) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/orasure-osur-q2-2026-earnings-call-transcript
- N5 | 2026-08-06 | www.nasdaq.com | OraSure Technologies Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/orasure-technologies-q2-earnings-call-highlights
- N6 | 2026-07-22 | www.nasdaq.com | FDA Grants OraSure's OraQuick Ebola 2.0 Antigen Test EUA Amid Central Africa Outbreak | https://www.nasdaq.com/articles/fda-grants-orasures-oraquick-ebola-20-antigen-test-eua-amid-central-africa-outbreak
- N7 | 2026-05-28 | www.nasdaq.com | Is Co-Diagnostics National Security’s Next Diagnostic Pick? | https://www.nasdaq.com/articles/co-diagnostics-national-securitys-next-diagnostic-pick
- N8 | 2026-05-06 | www.nasdaq.com | OraSure (OSUR) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/orasure-osur-q1-2026-earnings-transcript
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


